EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRCA1 , BRCA2 , and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

Caroline Stahnke Richau, Nicole de Miranda Scherer iD, Bruna Palma Matta, Elvismary Molina de Armas, Fábio Carvalho de Barros Moreira, Anke Bergmann, Claudia Bessa Pereira Chaves, Mariana Boroni, Anna Claudia Evangelista Dos Santos, Miguel Angelo Martins Moreira iD

Cancer Medicine · 2024-02 · 13 (3)

DOI: 10.1002/cam4.6729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.02.2024. Verfasst von Caroline Stahnke Richau und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tumoral Genetics and Virology Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian National Cancer Institute, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 3/4 of ovarian cancers are diagnosed in advanced stages, with the high‐grade epithelial ovarian carcinoma (EOC) accounting for 90% of the cases. EOC present high genomic instability and somatic loss‐of‐function variants in genes associated with homologous recombination mutational repair pathway (HR), such as BRCA1 and BRCA2 , and in TP53 . The identification of germline variants in HR genes in EOC is relevant for treatment of platinum resistant tumors and relapsed tumors with therapies based in synthetic lethality such as PARP inhibitors. Patients with somatic variants in HR genes may also benefit from these therapies. In this work was analyzed the frequency of somatic variants in BRCA1 , BRCA2 , and TP53 in an EOC cohort of Brazilian patients, estimating the proportion of variants in tumoral tissue and their association with progression‐free survival and overall survival.

Methods

The study was conducted with paired blood/tumor samples from 56 patients. Germline and tumoral sequences of BRCA1 , BRCA2 , and TP53 were obtained by massive parallel sequencing. The HaplotypeCaller method was used for calling germline variants, and somatic variants were called with Mutect2.

Results

A total of 26 germline variants were found, and seven patients presented germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 . The analysis of tumoral tissue identified 52 somatic variants in 41 patients, being 43 somatic variants affecting or likely affecting protein functionality. Survival analyses showed that tumor staging was associated with overall survival (OS), while the presence of somatic mutation in TP53 was not associated with OS or progression‐free survival.

Conclusion

Frequency of pathogenic or likely pathogenic germline variants in BRCA1 and BRCA2 (12.5%) was lower in comparison with other studies. TP53 was the most altered gene in tumors, with 62.5% presenting likely non‐functional or non‐functional somatic variants, while eight 14.2% presented likely non‐functional or non‐functional somatic variants in BRCA1 or BRCA2 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansFemaleCarcinoma, Ovarian EpithelialBrazilDNA RepairGerm CellsTumor Suppressor Protein p53BRCA1 ProteinBRCA2 Protein

Stichwörter der Autor:innen

BRCA1BRCA2TP53homologous recombination repair pathwayovarian cancersomatic mutation

Substanzen

TP53 protein, humanTumor Suppressor Protein p53BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Tumoral Genetics and Virology Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Bioinformatics and Computational Biology Laboratory, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Division of Pathology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Clinical Epidemiology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Gynecologic Oncology Department, Cancer Hospital II, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.

ORCID-Profile: Nicole de Miranda Scherer, Miguel Angelo Martins Moreira

Förderung

  • Brazilian National Cancer Institute
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Ministry of Health, Brazil
  • Swiss Bridge Foundation
  • Instituto Nacional do Câncer, Ministério da Saúde

Zitieren

APA

Richau, C. S., Scherer, N. M., Matta, B. P., de Armas, E. M., de Barros Moreira, F. C., Bergmann, A., Pereira Chaves, C. B., Boroni, M., Dos Santos, A. C. E., & Moreira, M. A. M. (2024). BRCA1 , BRCA2 , and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer. Cancer Medicine, 13(3). https://doi.org/10.1002/cam4.6729

Vancouver

Richau CS, Scherer NM, Matta BP, de Armas EM, de Barros Moreira FC, Bergmann A, et al. BRCA1 , BRCA2 , and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer. Cancer Medicine. 2024;13(3). doi:10.1002/cam4.6729

BibTeX
@article{Richau2024,
  author = {Richau, Caroline Stahnke and Scherer, Nicole de Miranda and Matta, Bruna Palma and de Armas, Elvismary Molina and de Barros Moreira, Fábio Carvalho and Bergmann, Anke and Pereira Chaves, Claudia Bessa and Boroni, Mariana and Dos Santos, Anna Claudia Evangelista and Moreira, Miguel Angelo Martins},
  title = {BRCA1 , BRCA2 , and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {3},
  doi = {10.1002/cam4.6729}
}
Kostenlos starten →